The drug development process faces challenges of efficiency and overall sustainability due in part to high research costs, lengthy development timelines, and late-stage drug failures. Novel clinical trial designs that target genetically identified participants represent a potentially disruptive paradigm shift that could reduce costs associated with drug development, improve patient outcomes, and further realize the goals of precision medicine. This workshop examined later stages in the drug development pipeline, including the design and implementation of genetics-based clinical trials.